BAYER AG
π©πͺGermany
- Country
- π©πͺGermany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
A Trial to Learn How BAY1834845 and BAY1830839 Affect Inflammation When Taken by Mouth Twice a Day for 7 Days in a Row in Healthy Male Participants
Phase 1
Completed
- Conditions
- Immune Mediated Inflammatory Diseases
- Interventions
- First Posted Date
- 2021-08-12
- Last Posted Date
- 2022-12-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 51
- Registration Number
- NCT05003089
- Locations
- π³π±
Center for Human Drug Research, Leiden, Netherlands
A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults
- First Posted Date
- 2021-08-10
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 47
- Registration Number
- NCT04999202
- Locations
- πΊπΈ
Brigette Harris Cancer Pavilion at Henry Ford Cancer Center - Detroit, Detroit, Michigan, United States
πΊπΈVirginia Cancer Specialists, PC, Fairfax, Virginia, United States
πΊπΈSarah Cannon Research Institute, Nashville, Tennessee, United States
A Pharmacy-based Study to Learn More About How Well Iberogast Works, How it Affects the Body, How it is Used, and User Satisfaction in Patients With Functional and Motility-related (Stomach and Bowel Movement-related) Gastrointestinal Diseases, Including Irritable Bowel Syndrome
Completed
- Conditions
- Functional and Motility Related Gastrointestinal Disorders Such as Irritable Bowel Syndrome and Functional Dyspepsia
- Interventions
- Drug: Iberogast (STW5, BAY98-7411)
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2021-08-06
- Lead Sponsor
- Bayer
- Target Recruit Count
- 843
- Registration Number
- NCT04993989
- Locations
- π©πͺ
Many Locations, Multiple Locations, Germany
A Study to Learn More About How a Smartphone App Called MyIUS Predicts Future Menstrual Bleeding in Women After They Have Begun Using Intrauterine Birth Control Method (a Birth Control Device is Inserted Into a Woman's Uterus by Her Doctor)
Completed
- Conditions
- Uterine Bleeding Profile Prediction
- Interventions
- Device: MyIUS app
- First Posted Date
- 2021-08-04
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Bayer
- Target Recruit Count
- 3045
- Registration Number
- NCT04989595
- Locations
- πΈπͺ
Many Locations, Many Locations, Sweden
A Study to Learn How Safe Elinzanetant is, How it Affects the Body, and How it Moves Into, Through and Out of the Body After Single and Multiple Doses in Japanese Healthy Female Adults
Phase 1
Completed
- Conditions
- Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men
- Interventions
- Drug: Elinzanetant (BAY3427080)Drug: Placebo
- First Posted Date
- 2021-07-29
- Last Posted Date
- 2022-03-29
- Lead Sponsor
- Bayer
- Target Recruit Count
- 62
- Registration Number
- NCT04981431
- Locations
- π―π΅
SOUSEIKAI Fukuoka Mirai Hospital, Fukuoka, Japan
Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort
Completed
- Conditions
- Prophylaxis of Recurrent Venous Thromboembolism in Cancer PatientsTreatment of Venous Thromboembolism in Cancer Patients
- Interventions
- Drug: Low molecular weight heparin (LMWH)Drug: Direct Oral Anticoagulants (DOAC)
- First Posted Date
- 2021-07-28
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Bayer
- Target Recruit Count
- 3708
- Registration Number
- NCT04979780
- Locations
- πΊπΈ
Many Locations, Multiple Locations, Connecticut, United States
NTRK Gene Fusion - Positive Advanced or Recurrent Solid Tumors, a Rare Cancer Caused by Specific Changes in the Genes
Recruiting
- Conditions
- Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion
- Interventions
- First Posted Date
- 2021-06-30
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 100
- Registration Number
- NCT04945330
- Locations
- π―π΅
Many locations, Multiple Locations, Japan
A Study to Learn About the Awareness and Knowledge That Doctors Have About the Safety and Safe Use Information for Androcur and Other Cyproterone Acetate Treatments in Europe
Completed
- Conditions
- Signs of Androgenisation in Women, e.g. Hirsutism, Androgenetic Alopecia, Acne and SeborrheaProstate CancerHypersexuality in MenSexual Deviations in Men
- Interventions
- Drug: Cyproterone Acetate (Androcur, BAY94-8367)
- First Posted Date
- 2021-06-14
- Last Posted Date
- 2022-01-12
- Lead Sponsor
- Bayer
- Target Recruit Count
- 600
- Registration Number
- NCT04925180
- Locations
- πͺπΈ
Many Locations, Multiple Locations, Spain
A Study to Learn About Venous Thromboembolism (VTE) Treatment With Rivaroxaban in Japanese Patients Using a Claims Database
Completed
- Conditions
- Treatment of Venous Thromboembolism
- Interventions
- First Posted Date
- 2021-06-11
- Last Posted Date
- 2023-01-12
- Lead Sponsor
- Bayer
- Target Recruit Count
- 2627
- Registration Number
- NCT04923139
- Locations
- π―π΅
Japan databases, Japan Databases, Japan
π―π΅Many Locations, Multiple Locations, Japan
RE-SEARCH Study: A Study to Learn How and in Which Amount Regorafenib is Given in Usual Practice to Patients in Spain: a Study Looking Back at Cases That Have Already Happened When the Study Begins.
Completed
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Other: No intervention
- First Posted Date
- 2021-06-09
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 242
- Registration Number
- NCT04920422
- Locations
- πͺπΈ
Many Locations, Multiple Locations, Spain
Β© Copyright 2025. All Rights Reserved by MedPath